1 / 13

15. Membrane stabilizer

15. Membrane stabilizer. R3 김형준. Peripheral sensory neurons 의 정상 구조와 fx 의 지속적인 derangement -> chronic persistence of pain sensation Input 을 받아들여 CNS 로 전달하는 길에 변형이 발생 – Central sensitization

wynter-cannon
Download Presentation

15. Membrane stabilizer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 15. Membrane stabilizer R3 김형준

  2. Peripheral sensory neurons의 정상 구조와 fx의 지속적인 derangement -> chronic persistence of pain sensation • Input을 받아들여 CNS로 전달하는 길에 변형이 발생 – Central sensitization • Tissue injury는 A-delta와 C fibers에 영향을 주어 activation의 threshold를 감소시킴 -> perception of pain – allodynia • Pathology가 위치한 곳에 다양한 ion channel이 증가하여 neuronal membrane excitability가 증가함 -> ectopic, abnormal impulse의 발생 • Sodium channel blocking agents Antiepileptics, local anesthetics and antiarrhythmics • Calcium channel blocking agents Gabapentin, w-conopeptides and calcium channel blockers

  3. SODIUM CHANNEL BLOCKERS • Anticonvulsants, local anesthetics and antiarrhythmics • The primary agents utilized for neuropathic pain are anticonvulsants • Primary therapy or adjunctive treatment for such process as trigeminal neuralgia, CRPS, diabetic neuropathy and post herpetic neuralgia • 일반적으로 용량은 safety standards내에서 patient comfort에 맞춰 조정되어야 함

  4. SODIUM CHANNEL BLOCKERS A. Anticonvulsants 1) Phenytoin (Dilantin) • Sodium channel blocking, excitatory glutamate의 분비를 막음, inhibiting ectopic discharges • Diabetic neuropathy의 치료에 사용됨 • 치료의 효과에 대한 상반되는 결과 때문에 neuropathic pain을 위한 first-line therapy로 고려하면 안됨 • Side effects – mentation, somnolence, giddiness, nystagmus, ataxia, gum hyperplasia (unique) • Activates the P450 enzyme system -> Careful assessment of cotherapy is warranted

  5. SODIUM CHANNEL BLOCKERS A. Anticonvulsants 2) Carbamazepine (Tegretol) • 화학적 구조가 TCA와 유사 • Inhibit pain via peripheral and central mechanism • Selectively blocks active fibers, 정상적으로 작동하는 C, A-delta nociceptive fibers에는 영향을 주지 않음 • Primary therapy for trigeminal neuralgia (tic doloreux), thalamic- mediated poststroke pain, postherpetic neuralgia, and diabetic neuropathy • Side effects - nausea, vomiting and sedation • 2-4개월마다 blood tests를 시행해야 함 <- agranulocytosis and aplastic anemia

  6. SODIUM CHANNEL BLOCKERS A. Anticonvulsants 3) Oxcarbazepine • The keto-analogue of carbamazepine -> CNS (dizziness) 또는 혈액학적 (leukopenia) 부작용이 적음 • Significant hyponatremia (<125mmol/L) may develop during first 3 months • Carbamazepine에 비해 side effect가 덜하여 많이 사용됨 4) Valproic acid • GABA A receptor에 작용 • Efficacy in migraine therapy • Side effects - gastrointestinal upset, somnolence, and dizziness

  7. SODIUM CHANNEL BLOCKERS A. Anticonvulsants 5) Lamotrigine (Lamictal) • Lamotrigine은 특이하게, sodium channel blocker로 작용하면서 pain propagation과 관련된 excitatory transmitter인 glutamate의 분비를 막음 • Major use is in trigeminal neuralgia, indication for cold-induced pain • Trigeminal neuralgia 치료 시 carbamazepine의 co-drug 또는 substitute로 사용 • Carbamazepine-resistant trigeminal neuralgia • Prevention of trigeminal neuralgia in susceptible pts. • Patient suffering from diabetic neuropathy • HIV-associated polyneuropathy • Side effects – rash (m/c)

  8. SODIUM CHANNEL BLOCKERS A. Anticonvulsants 6) Topiramate (Topamax) • In addition to affecting sodium and calcium channel, enhance GABA (inhibitory) neurotransmitter, and inhibit AMPA- type glutamate (excitatory) receptor • Adjunct로 사용해야 함 • Side effects – sedation • Potential for kidney stones and ocular glaucoma 7) Levetiracetam (Kepppra) • Relatively new antiepileptic • 작용기전은 아직 밝혀지지 않음

  9. LOCAL ANESTHETICS • Block the aberrant firing of the abnormal nerves • Not block normally conducting nerves 1) Lidicaine • The usual dose is 1 to 5 mg/kg IV • Antiarrhythmic, Bradycardia and cardiac depression is a potential risk -> 장기간 사용할 때는 EKG study 필요 • 5% lidocaine is available in transdermal application • Eutetic mixture of local anesthetics (EMLA) – topical local anesthetics 2) Mexilitene • Antiarrhythmic, oral analogue of lidocaine • For diabetic neuropathy, thalamic stroke pain, spasticity and myotonia

  10. CALCIUM CHANNEL BLOCKERS • Six different calcium channel current types found in nervous tissue - L, N, P, Q, R, T 1) Gabapentin • Binds at the alpha-2-delta subunit of the L-type calcium channel • GABA와 구조적으로 유사하나 GABA 수용체에 결합하지도 작용하지도 않고, GABA의 uptake와 metabolism에도 영향을 끼치지 않음 • Allodynic, burning, lancinating pain을 가진 환자는 positive benefit을 얻을 수 있음 • Postherpetic neuralgia, diabetic neuropathiy, CRPS, radiculopathy, postlaminectomy syndrome, poststroke syndrome, phantom limb pain, multiple sclerosis and etc • Favorable side-effect profile

  11. CALCIUM CHANNEL BLOCKERS 2) Zonisamide (Zonegran) • Blocking T-type calcium channels, and sodium channels 3) w-conopeptides • Derived from the venom of a marine snail • Action on N-type calcium channels • Intrathecal administration • HIV나 cancer population에서 opioid-resistant pain의 pain relief를 위해 연구되어옴 4) Nifedipine, Verapamil, Diltiazem, Nimodipine • Decreasing central sensitization • Do not have a role as monotherapy

  12. CALCIUM CHANNEL BLOCKERS 5) Magnesium • Antagonists of the NMDA receptor, including membrane stabilizing effect

  13. NUMBERS NEEDED TO TREAT (NNT) • NNT - the number of patients treated with a certain drug in order to obtain one patient with a defined degree of relief • NNT 50% - numbers needed to obtain one patient with>50% pain relief • The “numbers needed to harm” (NNH) - the number needed to treat with a certain drug before a patient before a patient experience a significant side effect

More Related